Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and CSO Joseph Araujo tell Proactive the group has released positive preclinical results from research on its Family 3 group of psilocybin compounds that could significantly improve the sustained effectiveness and safety profile of microdosing practices.
Lanthier and Araujo say research on the compounds, comprised of long-acting psilocybin side-chain restricted analogs, demonstrated “extended duration of action” and decreased effect size at the 5-HT2A receptor.
Lanthier says findings indicate the potential to change the paradigm of microdosing therapies by delivering the therapeutic benefits of psychedelics with limited potential to elicit a hallucinogenic experience at a wide range of effective doses.